CH573435A5 - - Google Patents

Info

Publication number
CH573435A5
CH573435A5 CH955873A CH955873A CH573435A5 CH 573435 A5 CH573435 A5 CH 573435A5 CH 955873 A CH955873 A CH 955873A CH 955873 A CH955873 A CH 955873A CH 573435 A5 CH573435 A5 CH 573435A5
Authority
CH
Switzerland
Application number
CH955873A
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CH573435A5 publication Critical patent/CH573435A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CH955873A 1972-07-01 1973-06-29 CH573435A5 (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6630172A JPS5512435B2 (he) 1972-07-01 1972-07-01

Publications (1)

Publication Number Publication Date
CH573435A5 true CH573435A5 (he) 1976-03-15

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
CH955873A CH573435A5 (he) 1972-07-01 1973-06-29

Country Status (15)

Country Link
US (1) US3925357A (he)
JP (1) JPS5512435B2 (he)
AT (1) AT325206B (he)
AU (1) AU469986B2 (he)
BE (1) BE801588A (he)
CA (1) CA996548A (he)
CH (1) CH573435A5 (he)
CS (1) CS168036B2 (he)
DE (1) DE2332840A1 (he)
FR (1) FR2190414B1 (he)
GB (1) GB1386566A (he)
HU (1) HU166029B (he)
NL (1) NL7308048A (he)
PL (1) PL92969B1 (he)
SE (1) SE402916B (he)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (he) * 1978-07-29 1980-02-13
ATE353900T1 (de) * 2001-02-24 2007-03-15 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (he) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
HU166029B (he) 1974-12-28
AT325206B (de) 1975-10-10
CA996548A (en) 1976-09-07
DE2332840A1 (de) 1974-01-17
PL92969B1 (he) 1977-04-30
US3925357A (en) 1975-12-09
CS168036B2 (he) 1976-05-28
FR2190414A1 (he) 1974-02-01
FR2190414B1 (he) 1976-07-02
BE801588A (fr) 1973-12-28
AU469986B2 (en) 1976-02-26
JPS4925121A (he) 1974-03-06
GB1386566A (en) 1975-03-12
SE402916B (sv) 1978-07-24
JPS5512435B2 (he) 1980-04-02
AU5760073A (en) 1975-01-09
NL7308048A (he) 1974-01-03

Similar Documents

Publication Publication Date Title
FR2190414B1 (he)
JPS4962027A (he)
JPS4977789A (he)
FR2180063A1 (he)
JPS4930539A (he)
JPS5148705B2 (he)
FR2190790A1 (he)
CS161295B1 (he)
JPS5039249Y2 (he)
JPS531897Y2 (he)
CS161309B1 (he)
CS159025B1 (he)
CS161282B1 (he)
JPS4980046U (he)
CS164520B1 (he)
CS165492B1 (he)
CS161025B1 (he)
CS160875B1 (he)
CS158500B1 (he)
JPS4889576U (he)
CS160396B1 (he)
JPS4987489U (he)
JPS4983105A (he)
JPS4931784A (he)
JPS4940318A (he)

Legal Events

Date Code Title Description
PL Patent ceased